SINGAPORE, Aug. 1, 2022 /PRNewswire/ — Vantage, an international multi-asset broker, is pleased to announce that it is launching a month-long donation drive in support of UNHCR, the UN Refugee Agency, to help refugees and internally displaced persons worldwide.
Vantage will be matching all donations from both new and existing clients, dollar for dollar, to support humanitarian efforts undertaken by UNHCR. The donation drive will run for one month until 30 August and may be extended based on client feedback.
UNHCR is a global organisation that has spent the last 70 years dedicated to saving lives, protecting rights and building a better future for refugees. Vantage and UNHCR jointly believe that everyone has the right to seek asylum and find safe refuge.
According to UNHCR, the number of people forced to flee conflict, violence, human rights violations, and persecution has now crossed the staggering milestone of 100 million for the first time on record, highlighting worldwide food insecurity, the climate crisis, war in Ukraine and other emergencies from Africa to Afghanistan as leading causes.
Ann Moey, Partnerships Manager at UNHCR says, “International solidarity is needed now more than ever, and all sectors of society can do their bit to help. Support from private sector partners like Vantage helps us inject vital energy into our humanitarian efforts, and allows us to deliver more assistance to vulnerable, displaced communities worldwide.”
The fundraising initiative is another step forward in Vantage’s corporate ESG journey, which was driven by the collective desire among its staff to make the world a better place. This donation drive follows closely after Vantage’s partnership with Supercar Blondie in participating in the Blue Carbon ESG initiative in Sardinia, Italy, as well as its multi-year sponsorship of the McLaren MX Extreme E team.
Sofiia Starchevska, ESG Ambassador at Vantage, said, “It’s infinitely more empowering and motivating knowing that your actions are one of many. It’s easier to see the power of collective, as opposed to individual, action, and this is what we want to achieve with this fundraising activity.”
“At Vantage, we know that the mental, emotional, and physical trauma of being displaced and having to rebuild in a strange land is a massive challenge, and we hope our initiative will double our support for refugees to seek protection and enable them to rebuild their lives. Together with UNHCR, we hope to make care our shared currency.”
Vantage is a global, multi-asset broker offering clients access to a nimble and powerful service for trading CFDs on Forex, Commodities, Indices, and Shares.
With more than 10 years of market experience. Vantage now has over 1,000 employees/personnel across more than 30 global offices.
Vantage is more than a broker. It provides a trusted trading ecosystem, an award-winning mobile trading app, and a faster and simpler trading platform that enables clients to take advantage of trading opportunities. Download the Vantage App on App Store or Google Play.
Be empowered to better capitalise on winning market opportunities when you trade smarter @vantage.
سنغافورة, 1 أغسطس 2022 /PRNewswire/ — يسر شركةVantage، وهي شركة وساطة دولية متعددة الأصول، أن تعلن أنها ستطلق حملة تبرعات لمدة شهر لدعم المفوضية السامية للأمم المتحدة لشؤون اللاجئين لمساعدة اللاجئين والنازحين داخليًا في جميع أنحاء العالم.
ستقوم Vantage بمطابقة جميع التبرعات المقدمة من العملاء الجدد والحاليين على حد سواء، بالدولار مقابل الدولار، لدعم الجهود الإنسانية التي تقوم بها UNHCR. ستستمر حملة التبرع لمدة شهر واحد حتى 30 أغسطس ويمكن تمديدها بناء على آراء العملاء.
المفوضية هي منظمة عالمية أمضت السنوات الـ 70 الماضية مكرسة لإنقاذ الأرواح وحماية الحقوق وبناء مستقبل أفضل للاجئين. تعتقد Vantage والمفوضية معًا أن لكل شخص الحق في طلب اللجوء والعثور على ملجأ آمن.
ووفقًا للمفوضية، تجاوز عدد الأشخاص الذين أجبروا على الفرار من الصراع والعنف وانتهاكات حقوق الإنسان والاضطهاد الآن معلمًا مذهلًا بلغ 100 مليون شخص لأول مرة على الإطلاق، مما يسلط الضوء على انعدام الأمن الغذائي في جميع أنحاء العالم، وأزمة المناخ، والحرب في أوكرانيا، وغيرها من حالات الطوارئ من أفريقيا إلى أفغانستان كأسباب رئيسية.
تقول آن موي، مديرة الشراكات في المفوضية: “هناك حاجة إلى التضامن الدولي الآن أكثر من أي وقت مضى، ويمكن لجميع قطاعات المجتمع القيام بواجبها للمساعدة. ويساعدنا الدعم المقدم من شركاء القطاع الخاص مثل Vantage على ضخ طاقة حيوية في جهودنا الإنسانية، ويسمح لنا بتقديم المزيد من المساعدات للمجتمعات الضعيفة والنازحة في جميع أنحاء العالم.”
وقالت صوفيا ستارشيفسكا، سفيرة الحوكمة البيئية والاجتماعية وحوكمة الشركات في Vantage، إنه أمر أكثر تمكينًا وتحفيزًا بلا حدود مع العلم أن إجراءاتك هي واحدة من العديد من الإجراءات. من الأسهل رؤية قوة العمل الجماعي، بدلًا من العمل الفردي، وهذا ما نريد تحقيقه من خلال نشاط جمع التبرعات هذا.”
“في Vantage، نعلم أن الصدمة العقلية والعاطفية والجسدية للنزوح والاضطرار إلى إعادة البناء في أرض غريبة تمثل تحديًا هائلًا، ونأمل أن تضاعف مبادرتنا دعمنا للاجئين لطلب الحماية وتمكينهم من إعادة بناء حياتهم. وبالتعاون مع المفوضية، نأمل أن نجعل الرعاية عملتنا المشتركة.”
Vantage هي وسيط عالمي متعدد الأصول يوفر للعملاء الوصول إلى خدمة ذكية وقوية لتداول العقود مقابل الفروقات في الفوركس والسلع والمؤشرات والأسهم.
إلى جانب التمتع بخبرة في السوق أكثر من 10 سنوات. يعمل لدى Vantage حاليًا أكثر من 1,000 موظفًا في أكثر من 30 مكتبًا حول العالم.
Vantage هي أكثر من مجرد وسيط. إنها توفر نظامًا بيئيًا للتداول موثوقًا، تطبيق تداول للجوّال الحائز على الجوائز ، ومنصة تداول أسرع وأبسط تمكن العملاء من الاستفادة من فرص التداول. قم بتنزيل تطبيق Vantage App على App Store أو Google Play.
كن قادرًا على الاستفادة بشكل أفضل من فرص السوق الرابحة عندما
AOP Health signed an agreement with Leukos Biotech for the further development of a newly discovered chemical substance. With this agreement AOP Health expands the hemato-oncology research area even further and provides additional treatment options for certain leukemia patients in the longer term.
Agnes Kohl, Chief Business Officer, AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group
Photo credit: Studio Koekart: Natascha Unkart & Isabelle Köhler
VIENNA, Austria, Aug. 01, 2022 (GLOBE NEWSWIRE) — The AOP Health Group (AOP Health) is a European pioneer for integrated therapies for rare diseases and in critical care headquartered in Vienna, Austria. The company focuses on research, development and global sales of innovative treatment solutions and specializes in therapies for rare diseases and intensive care. In early July, AOP Health signed an agreement with Leukos Biotech, a spin-off company founded by the Barcelona-based Josep Carreras Leukaemia Research Institute. The agreement signed by AOP Health covers the option for developments of the newly discovered chemical substance within any treatable indication, not limited to oncological or rare diseases.
Luis Ruiz-Avila, Chief Executive Officer Leukos Biotech
Copyright: Albert Mollon
Agreement sets basis for new areas of therapy
At first, AOP Health will focus on the development of treatment options for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Both are special disease types of leukemia that often start in the bone marrow. Agnes Kohl, Chief Business Officer of AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group explains: “Based on positive data, our plan is to expand the development for further orphan indications even outside of AML and MDS at a later stage. With this agreement, we may be able to broaden the portfolio within our therapeutic areas offering even more treatment options for patients.”
Development in cooperation with Leukos
As AOP Health focuses on rare, hemato-oncological cancers and has many years of experience in the development and commercialization of hemato-oncological treatments, the company will drive the further development of the substance in cooperation with Leukos based on a new mode of action. This could potentially turn into a milestone in the treatment of many blood cancer and other cancer patients. Luis Ruiz-Avila, Chief Executive Officer of Leukos Biotech: “We focus on developing new treatments for a wide variety of tumors. We were born to transform excellent science from the Josep Carreras Leukaemia Research Institute into valuable products for cancer patients in need, and this agreement is a very significant step in that direction. We are convinced that AOP Health is the right partner to turn this promising, novel mechanism of action into a clinical reality for the benefit of patients in a wide variety of unmet medical needs”.
About AOP Health
The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (“AOP Health”). The AOP Health Group is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the Group has become an established provider of integrated therapy solutions operating from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all its stakeholders on the other – especially the patients and their families as well as also the healthcare professionals treating them.
About Leukos
Leukos Biotech, SL (Leukos) is a spin-off company from the Josep Carreras Leukaemia Research Institute incorporated in Barcelona in 2015. The company is developing new treatments and diagnostic tools for a wide variety of tumors targeting the serotonin receptor HTR1B, which antitumoral potential was first described and patented by Leukos’ founder Dr. Ruth Risueño in her laboratory at the Josep Carreras Research Institute. Leukos’ main financial support is from private and institutional investors. The main shareholders are Inveready, CDTI Innvierte and the Josep Carreras Foundation. Besides investors’ support, Leukos has received non-dilutive grants and loans from the Catalan Government, the Spanish Government and the European Union in various programs.
About the Josep Carreras Foundation
The Josep Carreras Leukaemia Foundation was established in 1988 with the intention of contributing to finding a definitive cure for this disease. Its efforts are concentrated on four basic areas: administering the Spanish Bone Marrow Donor Registry (REDMO), scientific research, carried out by the Josep Carreras Leukaemia Research Institute, patient guidance through an online patient consultation channel, and reception apartments for patients who need to undergo treatment and have to spend a long time far from home.
About the Josep Carreras Leukaemia Research Institute
The Josep Carreras Leukaemia Research Institute, a public centre pertaining to the Generalitat de Catalunya’s CERCA network, was established in 2010 with the aim of furthering biomedical research and personalised medicine in the field of leukaemia and other onco-hematological diseases. It is the first research centre in Europe exclusively focussed on leukaemia and malignant blood diseases, and one of the very few in the world. The Josep Carreras Institutes has three coordinated but independent scientific campuses: University of Barcelona Hospital Clínic Campus, The Catalan Institute of Oncology/Germans Trias i Pujol Campus, and the Sant Pau – Autonomous University of Barcelona (UAB) Campus
About Inveready
Inveready is a leading alternative asset manager in Spain – investing in early-stage VC, growth VC, venture debt, strategic equity in listed companies, infrastructure and private equity – providing financing solutions to companies throughout their life-cycle. Founded in 2008, Inveready counts on 200 active companies, and more than €1bn of assets under management. Inveready has been investing in companies in the Life Sciences sector since 2008. Notable investments in this vertical are Atrys Health (listed on the Spanish market), EDESA Biotech (listed on Nasdaq), AVX Pharma (sold to Aerie Biotech) and PaloBiofarma (licensing agreement with Novartis). Inveready is headquartered in San Sebastian, and has other offices in Barcelona and Madrid. It has been recognized on multiple occasions by ASCRI and Preqin for the return on its funds and transactions (For more information, visit www.inveready.com).
SINGAPORE – Media OutReach – 1 August 2022 –MIMS, the region’s leading healthcare data and medical knowledge provider, is proud to announce that MIMS has successfully collaborated with Singapore’s Ministry of Health (MOH) on the editorial contents for the National Drug Formulary (NDF) website. The NDF is a MOH initiative under the National Pharmacy Strategy and the website is currently live at www.ndf.gov.sg.
The NDF website aims to establish a Singapore-specific, authoritative and national reference to guide evidence-based best practices for medication prescribing, dispensing, administration and monitoring by consolidating local clinical and drug-related information. NDF provides drug and post-marketing information from the Health Sciences Authority (HSA), subsidy information and drug guidance from the Agency for Care Effectiveness (ACE) and, general availability information from all of Singapore’s public healthcare institutions. MIMS, with its team of clinical editors, worked closely with MOH to organize and curate all these information for the NDF website within the stipulated timeframe.
“We at MIMS have been working to empower healthcare communities through our in-house products and services. The NDF website is an important initiative in Singapore’s healthcare landscape and is in line with our vision and mission.,” said Masaki Takahata, Chief Executive Officer of MIMS Group.
The Project Lead and Editorial Director at MIMS, Leong Wai Fun said, “We are delighted to have been an editorial partner, contributing to the content curation of NDF and enabling healthcare professionals to select safe and effective medicines for patients in Singapore.”
We look forward to such partnerships in the region and support clinicians in improving patient outcomes.
About MIMS
MIMS Group, a subsidiary of SMS Co. Ltd. (TYO 2175), has been offering diverse expertise for over 50 years in 17 countries and regions in Asia, Oceania and the Middle East with a focus on providing marketing support services to pharmaceutical companies, clinical decision support tools integrated in healthcare institutions as well as services to empower healthcare professionals in their daily operations. MIMS marketing platform services is spread across 10 countries mainly in South East Asia and has over 2.5 million healthcare professionals registered on the our online platform (www.mims.com), with drug directory services, medical communications, as well as media platform businesses.
MIMS has offices in the following countries & regions:
Singapore (Headquarters), Australia, China, Hong Kong SAR (China), Indonesia, India, Ireland, Japan, Korea, Malaysia, Myanmar, New Zealand, Philippines, Taiwan (China), Thailand, United Arab Emirates, and Vietnam.
سنغافورة – Media OutReach –تفخر شركة MIMS الشركة الرائدة في المنطقة في مجال إتاحة وتوفير بيانات الرعاية الصحية والمعلومات الطبية بالإعلان عن نجاح MIMS في التعاون مع وزارة الصحة في سنغافورة (MOH) في المحتوى التحريري لموقع الدليل الوطني للأدوية على الإنترنت (NDF) الدليل الوطني للأدوية مبادرة من وزارة الصحة في سنغافورة بموجب الاستراتيجية الوطنية للصيدلة والموقع موجود حالياً على الإنترنت على الرابط www.ndf.gov.sg.
يهدف موقع الدليل الوطني للأدوية إلى إنشاء دليل وطني رسمي سنغافوري للإرشاد إلى أفضل الممارسات المعتمدة على الأدلة بشأن وصف الأدوية وتوزيعها وتناولها ومراقبتها من خلال توحيد المعلومات الإكلينيكية المحلية والمتعلقة بالأدوية. يتيح الدليل الوطني للأدوية معلومات متعلقة بالأدوية ومعلومات ما بعد مرحلة التسويق من هيئة العلوم الصحية (HAS)، ومعلومات إضافية وإرشاد دوائي من هيئة كفاءة الرعاية (ACE) ومعلومات عامة متاحة من كافة مؤسسات الرعاية الصحية العامة في سنغافورة. وقد عمل فريق المحررين الطبيين عن كثب مع وزارة الصحة من أجل ترتيب وإعداد كافة هذه المعلومات لموقع الدليل الوطني للأدوية على الإنترنت خلال الفترة الزمنية المحددة.
وقد عملت MIMS على تمكين هيئات الرعاية الصحية من خلال خدماتنا ومنتجاتنا داخل الشركة. وقد قال السيد ماساكي تاكاهاتا المدير التنفيذي لمجموعة MIMS: إن موقع الدليل الوطني للأدوية مبادرة مهمة في قطاع الرعاية الصحية في سنغافورة تواكب رؤيتنا ومهمتنا.
كما قال السيد ليونج واي فون رئيس المشروع ومدير تحرير الموقع: لقد سررنا بكونناالشريك التحريري للموقع، وأننا ساهمنا في إعداد محتوى الدليل الوطني للأدوية ومكنا أخصائيي الرعاية الصحية من اختيار أدوية فعالة وآمنة للمرضى في سنغافورة.
ونحن نتطلع لمثل هذه الشركات في المنطقة ودعم الأطباء على تحسين نتائج مرضاهم.
نبذة عن MIMS
تعد مجموعة MIMS Group أحد أفرع شركة SMS Co. Ltd. (TYO 2175)، التي تقدِّم خبراتها المتنوعة لأكثر من خمسين عام في 17 دولة ومنطقة في آسيا وأوقيانوسيا والشرق الأوسط مع التركيز على توفير خدمات دعم التسويق لشركات الأدوية وأدوات دعم اتخاذ القرارات الطبية المدمجة في هيئات الرعاية الصحية وكذلك خدمات تمكين أخصائيي الرعاية الصحية في أعمالهم اليومية. منصة تسويق خدمات MIMS منتشرة في عشر دول وبالأساس في جنوب شرق آسيا، ولديها أكثر من 2.5 مليون أخصائي رعاية صحية مسجلين في منصتنا على الإنترنت (www.mims.com) وبها دليل خدمات دوائية، وخدمات تواصل طبية وكذلك شركات منصات إعلامية.
MIMS لديها مكاتب في الدول والأقاليم التالية:
سنغافورة (المقر الرئيسي)، أستراليا، الصين، هونج كونج المنطقة الإدارية الخاصة (الصين)، إندونيسيا، الهند، إيرلندا، اليابان، كوريا، ماليزيا، ماينمار، نيوزلاندا، الفلبين، تايوان (الصين)، تايلاند، دولة الإمارات العربية المتحدة وفيتنام.
WALTHAM, Mass and SHANGHAI, China, July 31, 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, announced that it has received approval of its Investigational New Drug (IND) application from the National Medical Products Administration (NMPA) of China for the initiation of a Phase 1/2 clinical study of ZB001 for the treatment of Thyroid Eye Disease (TED). The main objective of the Phase 1/2 is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZB001.
TED is a debilitating vison-threatening autoimmune disease that causes inflammation and fibrosis within the orbit of the eye. With no approved therapies for TED patients in China, treatment options are limited and often involve high doses of steroids associated with serious side effects or surgical intervention. ZB001 is a differentiated humanized monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R) intended for the treatment of TED.
“We are proud that the IND application for ZB001 was approved by the NMPA about two months following its submission, highlighting our team’s unique ability to efficiently execute on our development programs,” said Hua Mu, MD, PhD, Chief Executive Officer at Zenas. “We are excited to work with leading clinical experts in China to accelerate the development of ZB001 to address the significant unmet clinical need in thyroid eye disease.”
Zenas BioPharma licensed the exclusive rights to develop, manufacture and commercialize ZB001 (Viridian VRDN-001) and other compounds targeting IGF-1R in non-oncology indications in the greater China area from Viridian Therapeutics, Inc. (Viridian) in October 2020. After submitting an IND for VRDN-001 to the U.S. Food and Drug Administration in October 2021, Viridian initiated a Phase 1/2 clinical trial in December 2021 to evaluate proof of concept in TED patients in North America and released encouraging interim healthy volunteer data suggesting robust activity with excellent safety and tolerability of the candidate product.
About Zenas BioPharma
Zenas BioPharma is a global biopharmaceutical company based in the USA and China committed to becoming a leader in the development and commercialization of immune-based therapies for patients in the US, China and around the world. Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.
Investor and Media Contact:
Joe Farmer
Zenas BioPharma IR@zenasbio.com
